



Published in final edited form as:

*Cell Host Microbe*. 2019 September 11; 26(3): 359–368.e8. doi:10.1016/j.chom.2019.08.002.

## Structural basis for tetherin antagonism as a barrier to zoonotic lentiviral transmission

Cosmo Z. Buffalo<sup>1</sup>, Christina M. Stürzel<sup>2</sup>, Elena Heusinger<sup>2</sup>, Dorota Kmiec<sup>2</sup>, Frank Kirchoff<sup>2</sup>, James H. Hurley<sup>1,3,4,\*</sup>, Xuefeng Ren<sup>1,\*</sup>

<sup>1</sup>Department of Molecular and Cell Biology and California Institute for Quantitative Biosciences, University of California, Berkeley, Berkeley, CA 94720, USA

<sup>2</sup>Institute of Molecular Virology, Ulm University Medical Center, 89081 Ulm, Germany

<sup>3</sup>Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA

<sup>4</sup>Lead contact: James H. Hurley

### Summary

Tetherin is a host defense factor that physically prevents virion release from the plasma membrane. However, the Nef accessory protein of SIV engages the clathrin adaptor AP-2 to downregulate tetherin via its DIWK motif. As human tetherin lacks DIWK, antagonism of tetherin by Nef is a barrier to simian-human transmission of non-human primate lentiviruses. To determine the molecular basis for tetherin counteraction, we reconstituted the AP-2 complex with a simian tetherin and SIV Nef, and determined its structure by cryo-EM. Nef refolds the first  $\alpha$ -helix of the  $\beta$ 2 subunit of AP-2 to a  $\beta$  hairpin, creating a binding site for the DIWK sequence. The tetherin binding site in Nef is distinct from those of most other Nef substrates, including MHC-I, CD3, and CD4, but overlaps with the site for the restriction factor SERINC5. This structure explains the dependence of SIVs on tetherin DIWK and consequent barrier to human transmission.

### eTOC blurb

Simian to human lentiviral transmissions require adaptations in tetherin antagonism by viral Nef proteins. Buffalo et al. present the cryo-EM structure of SIV Nef complexed with tetherin and AP-2, providing insight into the importance of the tetherin DIWK motif and its role as a barrier to SIV spread in humans.

### Graphical Abstract

\*Corresponding authors: James H. Hurley, jimhurley@berkeley.edu and Xuefeng Ren, snowren@berkeley.edu.


Author Contributions

J.H.H. and X.R. conceived the overall project. C.Z.B., X.R., C.M.S., E.H., and D.K. performed research. J.H.H., X.R. and F.K. supervised research. J.H.H., C.Z.B., X.R. and F.K. wrote the initial manuscript and all participated in editing.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declaration of Interests

The authors declare no competing interests.



## Keywords

HIV; SIV; clathrin; adaptor protein; host-factor restriction; trafficking; cryo-EM

## Introduction

Human and simian immunodeficiency viruses (HIV and SIV) depend on factors known as accessory viral proteins for their efficient replication and spread (Collins and Collins, 2014). Lentiviral accessory proteins, including Nef, Vpu, Vif, Vpr, and Vpx, counteract host defenses by redirecting cellular pathways for the benefit of the virus (Collins and Collins, 2014; Malim and Bieniasz, 2012). In some cases, activities of these viral proteins overlap or compensate for one another to ensure viral fitness. The counteraction of the host factor tetherin by lentiviral Nef, Env, and Vpu is a prominent example (Sauter et al., 2009). Tetherin (also known as BST2) is an interferon-induced antiviral restriction factor that physically tethers nascent virions to the plasma membrane of the viral producer cell, preventing release and marking the cell for immune detection (Neil et al., 2008). The sequences of tetherin orthologs vary considerably between even closely related species and tetherin is counteracted by viral accessory proteins in a species-specific manner (Jia et al., 2009; Zhang et al., 2009). Most notably, the lack of an otherwise conserved (G/D)DIWK motif in human tetherin confers resistance to downregulation by the viral protein Nef used by most SIVs to counteract this restriction factor. Thus, antagonism of tetherin is a major barrier to successful simian-human transmission of non-human primate lentiviruses, the origin of HIV (Sauter and Kirchhoff, 2019). Here, we elucidate the structural basis for antagonism of (G/D)DIWK-containing simian tetherin by SIV Nef in near-atomic detail.

The accessory proteins Nef and Vpu of HIV and SIV reconfigure the membrane protein repertoire of host cells by hijacking clathrin-coated vesicles (CCVs) to sequester and/or degrade target cargoes (Pereira and daSilva, 2016). The heterotetrameric adaptor protein (AP) complexes are primarily responsible for connecting cargo and membranes to clathrin.

The trans-Golgi network (TGN) and plasma membrane complexes AP-1 and AP-2, respectively, are major direct targets of Nef and Vpu (Collins and Collins, 2014; Pereira and daSilva, 2016). APs consist of two large solenoidal subunits ( $\alpha$  or  $\gamma$  and  $\beta$ ), a medium subunit  $\mu$ , and a small subunit  $\sigma$  (Traub and Bonifacino, 2013). All known host cargoes interact with APs via either tyrosine-based sorting signals (Yxx $\Phi$ ) that bind to the C-terminal domain (CTD) of  $\mu$  or dileucine signals (ExxxL(L/V)) that bind to a hemicomplex of  $\alpha/\gamma$  and  $\sigma$  (Traub and Bonifacino, 2013). Nef and Vpu both use (ExxxL(L/V)) motifs to hijack AP complexes (Aiken et al., 1994; Bresnahan et al., 1998; Craig et al., 1998; Jia et al., 2014). In solution, the binding sites on the AP complexes for the Yxx $\Phi$  and ExxxL(L/V) motifs are hidden in the locked conformation of APs (Canagarajah et al., 2013; Jackson et al., 2010). Upon activation by the small GTPase Arf1 at TGN membranes (Ren et al., 2013) or the lipid PI(4,5)P<sub>2</sub> at the plasma membrane (PM) (Jackson et al., 2010), the  $\mu$  CTD undergoes a large conformational change, unlocking and activating the complex.

To overcome barriers to cross-species transmission during primate lentiviral evolution, the task of antagonizing tetherin has shifted repeatedly between Nef and Vpu (Sauter and Kirchhoff, 2019). Most SIV including SIVcpz, SIVgor, and SIVsmm, the direct precursors of HIV-1 and HIV-2, respectively, use their Nef protein to target AP-2 at the PM by a mechanism whose details are still unknown (Jia et al., 2009; Sauter et al., 2009; Schmokel et al., 2011; Zhang et al., 2011). Pandemic group M HIV-1 strains switched from Nef to Vpu to hijack AP-1 at the TGN, using its dileucine motif to unlock AP-1 and free the  $\mu$  CTD to target a variant Tyr motif in the cytosolic tail of tetherin (Jia et al., 2014; Kueck et al., 2015). In contrast, Nef proteins from the epidemic HIV-1 group O evolved to interact with a region in human tetherin sequence adjacent to the (G/D)DIWK deletion bridging the  $\mu$  and  $\sigma$  subunits of AP-1 in *trans* and promoting a unique trimeric assembly of AP-1 to sequester tetherin at the TGN (Kluge et al., 2014; Morris et al., 2018). The remaining N and P groups of HIV-1 have gained little if any activity against human tetherin and were only detected in a few individuals. Here, we report on the Nef of SIVsmm infecting sooty mangabeys. SIVsmm uses Nef and its envelope (Env) glycoprotein as tetherin antagonist in its natural simian host and represents the direct ancestor of HIV-2 and of SIVmac causing simian AIDS in rhesus macaques (Sauter and Kirchhoff, 2019). SIVsmm managed to cross the species barrier from monkeys to humans on at least 9 occasions possibly because its Env protein shows some activity against human tetherin (Heusinger et al., 2018). However, the Nef proteins of HIV-2 gained little if any activity against human tetherin (Heusinger et al., 2018; Le Tortorec and Neil, 2009) and HIV-2 shows lower transmission rates and is much less prevalent than HIV-1. We show by cryo-EM and allied methods that simian tetherin is targeted in a unique way by the induced refolding of the  $\beta$  subunit of AP-2 from an  $\alpha$ -helix to a  $\beta$ -hairpin, creating a binding site for the (G/D)DIWK motif in a crevice between the new  $\beta$ -hairpin and Nef.

## Results

### Cooperative interaction between AP-2, simian tetherin and SIVsmm Nef

In the absence of the lipid membrane, the AP-2 core adopts a locked conformation that obscures the binding sites for recruiting both physiological cargoes and Nef (Fig. 1A). In

order to promote the open conformation of AP-2 in the absence of lipid membranes, we generated the unlocked tetrameric core construct AP2  $\mu^C$ , in which the  $\mu 2$  CTD that is dispensable for Nef binding to AP-2 (Chaudhuri et al., 2007), is deleted. We compared the SIVsmm Nef and simian tetherin binding of this construct to that of the AP-2  $\alpha$ - $\sigma 2$  hemicomplex (“AP2<sup>hemi</sup>”). AP2<sup>hemi</sup> binds tightly to HIV-1 NL4–3 Nef in the absence of cargo (Ren et al., 2014), but binds only very weakly to SIVmac239 Nef (96–237) and rhesus (rh) tetherin (Serra-Moreno et al., 2013). By tetherin tail-MBP pull down assay, we observed a tight cooperative interaction between rh tetherin, SIVsmm Nef and AP2  $\mu^C$  in combination. In contrast, the tetherin tail did neither bind to AP2  $\mu^C$  or SIVsmm Nef alone nor interact with AP2<sup>hemi</sup>, even in the presence of SIVsmm Nef (Fig 1B). We used fluorescence polarization (FP) to determine that Alexa488-tetherin tail bound to AP2  $\mu^C$  and SIVsmm Nef with  $K_d = 2.7 \mu\text{M} \pm 0.1 \mu\text{M}$  (Fig 1C, D), while binding to the separate components or to AP2<sup>hemi</sup> was undetectable. These data indicate that simian tetherin binds to the AP-2 core and SIVsmm Nef in a cooperative and high affinity ternary complex that requires elements of the full AP-2 tetramer.

### CryoEM structure of the AP2 $\mu^C$ , SMM tetherin and SIVsmm Nef complex

The structure of the complex of AP2  $\mu^C$  cross-linked to the tetherin-SIVsmm Nef complex was determined by cryo-EM at a resolution of 3.8 Å (Fig. 2A, B, S1–3, Movie S1). Side-chain density was visible throughout most of the density map, including most of all four subunits of AP-2, SIVsmm Nef, and SMM tetherin. An atomic model was built on the basis of the crystal structures of unlocked AP-2 (Jackson et al., 2010) and NL4–3 HIV-1 Nef bound to AP2<sup>hemi</sup> (Ren et al., 2014). The tetherin tail and unique regions of SIVsmm Nef were built *ab initio* (Fig. 3A–C). The conformation of the dileucine loop in the cross-linked SIVsmm Nef complex is essentially identical to the conformation previously seen in the uncrosslinked NL4–3 complex (Ren et al., 2014) (Fig. 3D), showing that the presence of the crosslink did not perturb the structure. The overall conformation of AP2  $\mu^C$  is similar to that of the unlocked AP-2 core (Jackson et al., 2010), with the pivotal exception of the  $\beta 2$  N-terminus.

### SIVsmm Nef refolds the N-terminus of $\beta 2$ -adaptin

An interface was observed between the  $\beta 2$  subunit and SMM tetherin (Fig 3A), that was not found in previous structures of NL4–3 Nef complexes with APs (Jia et al., 2012; Morris et al., 2018; Ren et al., 2014; Shen et al., 2015). Despite a large conformational change upon unlocking, the N-terminus of  $\beta 2$  (residues 13–24) comprises helix  $\alpha 1$ , preceded by random coil. When AP2  $\mu^C$  binds to SMM tetherin and SIVsmm Nef, the flexible loop (residues 6–12) along with the first turn of  $\alpha 1$  (residues 14–17) refold into a  $\beta$  hairpin structure not previously described in AP structures (Fig. 4A, Movie S2). This hairpin conformation appears to be stabilized by direct interactions with both SIVsmm Nef and the SMM tetherin tail (Fig. 4A, B).

To corroborate the refolding of the  $\beta 2$  N-terminus, we used hydrogen-deuterium exchange coupled to mass spectrometry (HDX-MS) to monitor changes in the dynamics of AP-2 protein upon binding tetherin and SIVsmm Nef. When bound to SIVsmm Nef only, the  $\beta 2$  N-terminus underwent rapid exchange, similar to the unbound state (Fig. 4C). However,

when bound to both tetherin and Nef,  $\beta 2$  (peptide 7–18) underwent 40% less HD exchange (30 s) (Fig. 4C, S4A). Slower deuteration was also seen in  $\alpha$  and  $\sigma 2$  residues in SIVsmm Nef binding regions (Fig. S4B, C), as expected. The finding that protection from amide HD exchange in the  $\beta 2$  N-terminus depends on the presence of both SIVsmm Nef and tetherin strongly supports the conclusions drawn from the cryo-EM structure that the presence of these two molecules together is required for refolding of this region.

Side-chains of the induced  $\beta 2$  hairpin present a wall of exposed hydrophobic surface for interactions with tetherin and Nef. These include Tyr6, Phe7, Thr8, Thr9, and Ile15 (Fig. 4B). We generated double and triple mutations to test the role of  $\beta 2$  N-terminal residues in the interface (Fig. 4D). Mutation of residues in both the first (residue 5–7 and 8–9) and second  $\beta$ -strands (residue 15–16) disrupted complex formation. Mutation of Lys11 and Lys12 at the turn connecting the two strands had no effect, however, consistent with their high solvent exposure.

SIVsmm Nef residues 179–189 are the ones most intimately involved in interacting with the  $\beta 2$  hairpin structure (Fig. 4A, B, Fig. 5A, B). This key section is well-conserved in HIV-1 Nef (Fig. 5A). The SIVsmm Nef main chain from residues 179–182 folds into a  $\beta$  strand that complements the  $\beta 2$  hairpin, completing a three-stranded  $\beta$ -sheet spanning SIVsmm Nef and  $\beta 2$ . SIVsmm Nef side-chains of Val180, Ser183, Glu185, and Ala186 all interact with  $\beta 2$  (Fig. 5B). The mutations made to disrupt the function of this region, V180D/S183Y and E185A/A186H, severely reduced binding as judged by FP (Fig. 5C). Others immediately following these, including Gln187, Glu188, Asp189, and Glu190 (the E of the EXXXL(L/V) motif) contact SMM tetherin and  $\sigma 2$ , and lead into the heart of the dileucine highlighting how this short stretch of Nef sequence forms a central nexus between all of the other elements of the complex (Fig. 5B). The relatively solvent exposed residues 187–188 seem to be non-essential, while mutation of Asp189 or Glu190 have strong reductions in binding (Fig. 5C). Collectively, the cryo-EM, HDX-MS, binding, and mutational data lead to a clear and consistent picture of how tetherin and Nef-induced refolding of the  $\beta 2$  N-terminus creates a binding site for the (G/D)DIWK motif in the cytoplasmic tail of simian tetherin.

### The (G/D)DIWK binding pocket

EM density was resolved for residues 11–19 of SMM tetherin (Fig. 3A), with Ile16 and Trp17 serving as landmarks for the register and direction of the tetherin tail. Trp17 is the linchpin of the binding site, and its mutation leads to a severe loss in affinity for the complex (Fig. 4E). Its side-chain is wedged into a pocket between the turn of the AP-2  $\beta 2$  subunit N-terminal hairpin on the one hand, and SIVsmm Nef strands  $\beta 1$  and  $\beta 4$  and the dileucine loop on the other. The C $\alpha$  of  $\beta 2$  subunit Gly13 is in direct contact with the tetherin Trp side-chain (Fig. 3C), the closest direct contact between tetherin and AP-2. Tyr133 from Nef strand  $\beta 1$  forms one side of the Trp indole-binding pocket. The remainder of the pocket is formed by residues from Nef strand  $\beta 4'$  and H4, and most critically, the back side of the dileucine loop. Nef strand  $\beta 4'$  contributes Val182 and H4 contributes Ala186. While Nef residues Leu194 and Val195 are the critical plug that connects Nef to the “socket” of the dileucine binding site in  $\sigma 2$ , His192 and His196, which point in the opposite direction, are key parts of

the Trp binding pocket. The His192 side-chain imidazole stacks against the Trp indole, forming the most extensive interaction of any residue in the pocket.

Of the remaining tetherin side-chains observed, Ile16 forms van der Waals contacts with the Leu21 and Arg24 side chains of the Nef N-terminal H0 (Fig. 3C). Density for Asp15 was missing, as often seen in EM density and as seen for most of the Asp and Glu in this reconstruction. On the basis of the surrounding stereochemical constraints, the side-chain was placed such that salt bridges are formed both with His196 of the Nef dileucine loop, and with Arg138 of Nef H2 (Fig. 3C). Mutation of either Asp15 or Ile16 disrupts complex formation (Fig. 4E), consistent with the multiple structural interactions. Single mutations in other residues had little impact on binding, with the exception of Lys18 and Glu19 (Fig. 4E). Lys18 forms a salt bridge with Nef Asp189 (Fig. 3C), which likely accounts for the 2.5-fold reduction in affinity in the K18D mutant. Density for the surface-exposed Glu19 was not visualized, however, so the structural basis for the effect of E19A is unclear. These data are gratifyingly consistent with biological observations of the critical role of the (G/D)DIWK motif for counteraction by SIV Nef.

### **$\alpha$ - $\sigma$ 2 engagement by SIVsmm Nef**

The dileucine loop of SIVsmm Nef interacts with the AP-2  $\alpha$ - $\sigma$ 2 hemicomplex in a similar manner to HIV-1 NL4-3 Nef (21), but the SIVsmm Nef helix H5 is more regular than its NL4-3 counterpart and has additional interactions. SIVsmm Nef Trp203 anchors the C-terminus of H5 to a pocket formed by residues 60-62 of  $\sigma$ 2, which are protected from HDX on complex formation (Fig. S4C). The mutation W203S severely impacts complex formation (Fig. 5C). SIVsmm Nef Asp204 and Pro206 also make SIV-specific interactions with  $\sigma$ 2 (Fig. 5B). Consistent with the structural observations, HDX-MS showed a very high level of protection for the Nef dileucine loop when the complete ternary complex was formed (Fig. S5). These findings show that SIVsmm Nef is capable in forming a tight and highly ordered complex with  $\alpha$ - $\sigma$ 2 *via* the dileucine loop.

### **Residues specifically disrupting anti-tetherin activity of SIVsmm Nef**

To examine the relevance of the specific residues for Nef function, we introduced single or combined mutations of H192D, H196D, W203S, and their combinations, into the bicistronic pCG expression vector and in proviral HIV-1 NL4-3 constructs coexpressing the SIVsmm Fwr1 Nef protein and eGFP via an IRES element. H192D and H196D were designed to disrupt interactions with tetherin Trp17 and Asp15, respectively. W203S was designed to disengage Nef from the  $\alpha$ - $\sigma$ 2 subcomplex. Western blot analysis showed that the mutant Nef proteins were efficiently expressed (Fig. S6A). One exception was that the Y133D substitution, another mutant made to probe the Trp17 binding site, showed lower levels of expression than the parental SIVsmm Nef and was thus excluded from functional analyses. To test anti-tetherin activity, we cotransfected HEK293T cells with *env*- and *vpu*-deficient HIV-1 NL4-3 proviral constructs containing wild type or mutant SIVsmm *nef* alleles, as well as SMM tetherin and Env expression or control plasmid. Subsequently, we measured tetherin surface levels, infectious virus yield and p24 antigen release two days later. Mutation of H192D or W203S disrupted the ability of SIVsmm Nef to downregulate cell surface expression of SMM tetherin (Fig. 6A) and to enhance infectious virus yield (Fig. 6B)

and p24 antigen release (Fig. S6B). In comparison, H196D did not affect the ability of SIV<sub>smm</sub> Nef to downregulate SMM tetherin but resulted in a phenotype intermediate between wt and *nef*-defective SIV<sub>smm</sub> in infectious virus yield assays. From these phenotypes we conclude that Nef engagement with the AP-2  $\alpha$ - $\sigma$ 2 subcomplex and with tetherin Trp17 is essential for SMM tetherin downregulation, while tetherin Asp15 engagement is less so.

To further analyze the impact of the mutations on SIV<sub>smm</sub> Nef function, we examined their effect on viral infectivity in the presence of SERINC5, a recently described restriction factor that impairs virion infectivity (Rosa et al., 2015; Usami et al., 2015). In contrast to tetherin antagonism, Nef counteracts SERINC5 and modulates various immune receptors in a species-independent manner (Rosa et al., 2015; Usami et al., 2015). Coexpression of SERINC5 reduced infectivity of the *nef*-defective control HIV-1 construct by >95% but did not affect the infectiousness of VSV-G pseudotyped viral particles (Fig. 6C). The H192D mutation impaired and W203S almost fully disrupted the anti-SERINC5 activity of SIV<sub>smm</sub> Nef, while H196D resulted in an intermediate phenotype (Fig. 6C). As seen for SMM tetherin downregulation, the AP-2  $\alpha$ - $\sigma$ 2 subcomplex and Trp17 binding pocket are both essential, while the Asp15 binding site also contributes. These data suggest that SERINC5 and SMM tetherin downregulation involve a common mode of AP-2  $\alpha$ - $\sigma$ 2 engagement (Fig. 7). Moreover, it suggests that residues of SERINC5 bind to Nef through the backside of a similar conformation of the dileucine loop as SMM tetherin (Fig. 7).

To determine the impact of the above-mentioned amino acid changes on the ability of SIV<sub>smm</sub> Nef to modulate various cellular immune receptors, we transduced human peripheral blood mononuclear cells (PBMCs) with VSV-G pseudotyped *env*- and *vpu*-deficient HIV-1 NL4-3 based IRES-eGFP constructs containing different *nef* alleles and performed flow cytometric analysis (Fig. S6C). In agreement with published data (Schmokel et al., 2009), the parental SIV<sub>smm</sub> Nef efficiently downregulated CD4, CD3, and (to a lesser extent) MHC-I, CD28, and CXCR4 in primary human cells (Fig. 6D). Although mutation of H192D fully disrupted the anti-tetherin and anti-SERINC5 activities of SIV<sub>smm</sub> Nef, it did not reduce its ability to downregulate any of these immune receptors from the cell surface (Figs. 6D, S6C). Similarly, mutation of H196D had little if any effect on the efficiency of Nef-mediated modulation of CD3, MHC-I, CD28, and CXCR4, although it moderately attenuated down-modulation of CD4. In comparison, W203S strongly reduced downregulation of CD4 and CXCR4 and fully disrupted the effect on CD28, while having no effect on modulation of MHC-I or CD3 (Fig. 6D). Similar observations on the role of SIV<sub>mac</sub> Nef residues His196 and Trp203 were recently reported in the context of MHC escape mutants (Schouest et al., 2018). The W203S data show that AP-2  $\alpha$ - $\sigma$ 2 engagement is a relatively general theme in the downregulation of many Nef substrates, including SMM tetherin, SERINC5, CD4, CD28, and CXCR4. On the other hand, the usage of the backside of the dileucine loop as probed by H192D appears to be limited to a much smaller set of substrates comprising, so far just SMM tetherin and SERINC5 (Fig. 7).

Nef counteracts tetherin in a species-specific manner, precluding meaningful analysis of tetherin antagonism by SIV<sub>smm</sub> Nef in human-derived PBMCs. Via studies in primary rhesus-derived T cells, we thus introduced the above-mentioned mutations in Nef in the

infectious molecular SIVmac239 clone that is commonly used for studies on AIDS pathogenesis and vaccine development in the SIV/macaque model. Similar to the results obtained for the SIVsmm Nef (Fig. 6A–D), mutation of H192D impaired the ability of SIVmac239 Nef to counteract rhesus tetherin but had little if any disruptive effect on downmodulation of CD4, MHC-I and CD3 in rhesus PBMCs (Fig. 6E, S6D). In comparison, mutation of H196D or W203S significantly reduced anti-tetherin activity as well as the efficiency of CD4 downmodulation (Fig. 6E). Altogether, our results confirmed the key role of H192, H196 and W203 for tetherin counteraction by SIV Nef in primary virally infected monkey cells. The structural findings thus reflect general features of Nef function in SIV from two different monkey species in cultured and primary cells.

## Discussion

It was discovered a decade ago that the sensitivity of simian tetherin to antagonism by SIV Nefs maps to a (G/D)DIWK motif in the N-terminal tail of tetherin that is missing in its human ortholog (Jia et al., 2009; Sauter et al., 2009; Zhang et al., 2009). The structure explains how each of the four residues in the most conserved central DIWK part of this motif interact with AP-2 and SIVsmm Nef, and is beautifully congruent with the biological data. The structural and binding data explain how the absence of this motif in human tetherin renders it resistant to downregulation from the cell surface by SIV Nefs. The inability of SIV to antagonize human tetherin is now considered to be one of the major hurdles to successful simian-human zoonotic transmission (Sauter and Kirchhoff, 2019). Our data thus provide the structural basis for a transmission barrier that helps to protect humans from efficient primate lentiviral transmission.

The involvement of the AP-2  $\beta$ 2 subunit in recognizing both Nef and cargo sets the SIVsmm Nef and tetherin interaction apart from all other physiological or Nef-hijacked sorting events reported to date. All known physiological cargoes that bind to AP cores do so through either the Tyr or dileucine motif binding sites in the  $\mu$  and the  $\sigma$  subunits, respectively (Fig 7A) (Traub and Bonifacino, 2013). Nef downregulation of MHC-I (Le Gall et al., 1998) occurs principally through the Tyr binding site on the CTD of  $\mu$ 1. The difference is consistent with the null effect of all of the SIVsmm Nef mutants tested on MHC-I downregulation. CD4 downregulation by Nef- appears to be mediated by a site on Nef wedged between strand  $\beta$ 1 and helix H2 (Manrique et al., 2017), which is not in direct contact with AP-2. SIV tetherin downregulation shares with CD4, CD28, and CXCR4 a dependence on the engagement of the dileucine loop (Aiken et al., 1994; Bresnahan et al., 1998; Craig et al., 1998; Leonard et al., 2011) with the  $\alpha$ - $\sigma$ 2 hemicomplex, consistent with the W203S phenotype in tetherin and CD4 downregulation. It is remarkable that such a small protein as Nef can bind and hijack the AP complexes in so many different ways. This multifunctionality confers robustness to viral mutation and host variation.

Our results suggest that many downregulatory functions of Nef are structurally and genetically separable. Perhaps most notably, mutation of H192D impairs the ability of SIVsmm and SIVmac Nef to antagonize tetherin and SERINC5 during the late stage of the viral replication cycle but had no disruptive effect on the modulation of various immune receptors (CD4, CD3, CD28, MHC-I and CXCR4) required for viral immune evasion



throughout the viral life cycle (Fig 7B). Thus, this mutation may help probe the relevance of early vs. late Nef functions for viral replication and pathogenicity *in vivo* in non-human primate models for AIDS.

His192 is conserved in most monkey SIVs but not the ape and human viruses. On the other hand His196 is conserved across all Nefs, and H196D is defective in SERINC5 downregulation in human cells. The proximity of His196 to the  $\beta 2$  hairpin interface, and the conservation in HIV-1 of the Nef strand  $\beta 4$  involved in hairpin refolding suggests that the  $\beta 2$  hairpin participates in HIV-1 Nef downregulation of SERINC5. The apparent lack of a normal physiological role for the  $\beta 2$  hairpin in AP-2-dependent cargo sorting suggests that this interface could be targeted therapeutically by Nef antagonists to restore SERINC5 expression and block viral infectivity.

Different HIV strains have adapted to their human hosts with different degrees of success through both Nef-dependent and independent mechanisms. HIV-1 O-Nefs adapted to target a tetherin sequence adjacent to the DIWK deletion (Kluge et al., 2014) in conjunction with the  $\mu 1$  subunit of AP-1. When bound to human tetherin and  $\mu 1$ , HIV-1 O-Nef bridges the  $\beta 1$ -  $\mu 1$  and  $\gamma 1$ - $\sigma 1$  hemicomplexes of two different AP-1 tetramers in *trans*. This *trans* bridging mode, in contrast to the *cis* bridge described here for SIVsmm Nef, leads to AP-1 trimerization and formation of a structure capable of sequestering tetherin at the TGN (Morris et al., 2018). HIV-2 Nefs never recovered the ability to target tetherin, and HIV-2 is dependent on Env for tetherin counteraction. The pandemic M-group HIV evolved a potent Vpu counteraction of a tetherin, which however, uses some of the same principles as Nef-dependent counteraction. HIV-1 M-Vpu has a dileucine that can engage the  $\gamma 1$ - $\sigma 1$  hemicomplex of AP-1 and targets the same DIWK deletion-proximal sequence in tetherin and the same site on  $\mu 1$  as HIV-1 O-Nefs (Jia et al., 2014). All of the adaptations whereby HIVs counteract human tetherin involved major changes in mechanism, either using Nef to hijack a different AP complex through different sites, or using other proteins entirely. This illustrates that the barrier caused by the absence of DIWK in human tetherin cannot be overcome simply by modifying and repurposing the pre-existing DIWK binding site in SIV Nefs. On the other hand, the fact that the barrier ultimately was overcome repeatedly and in different ways highlights the multiplicity of entry points to the host trafficking machinery and the versatility of viral proteins through evolution.

## STAR METHODS

### LEAD CONTACT AND MATERIALS AVAILABILITY

All plasmids generated in this study are outlined in the Key Resources Table and are available upon request. Further information and requests for resources should be directed to and will be fulfilled by the Lead Contact, Xuefeng Ren (snowren@berkeley.edu).

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

**Cell lines**—Human Embryonic Kidney (HEK) 293T cells (DuBridg e et al., 1987) were obtained from the American Type Culture Collection (ATCC) and TZM-bl reporter cells (Platt et al., 1998) were kindly provided by Drs. Kappes and Wu and Tranzyme Inc. through

the NIH AIDS Reagent Program. Both cell lines were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin. TZM-bl cells express CD4, CCR5 and CXCR4 and contain the  $\beta$ -galactosidase gene under the control of the HIV-1 promoter.

**Primary human cell cultures**—Experiments involving human blood were reviewed and approved by the Institutional Review Board (i.e. the Ethics Committee of Ulm University). Individuals and/or their legal guardians provided written informed consent prior to donating blood and all human-derived samples were anonymized before use, therefore the age and gender of the donors is not known to the experimenters. Peripheral blood mononuclear cells (PBMCs) from healthy human donors were isolated using lymphocyte separation medium (Biocoll separating solution; Biochrom), stimulated for 3 days with phytohemagglutinin (PHA; 2 µg/ml), and cultured in RPMI 1640 medium with 10% fetal calf serum and 10 ng/ml interleukin-2 (IL-2).

## METHOD DETAILS

**Plasmid construction**—The four subunits of AP2<sup>µC</sup> were subcloned into pST39 vector by restriction cloning (Selleck and Tan, 2008). DNAs coding for the four subunits of AP2<sup>µC</sup> were as follows: rat  $\sigma$ 2 full-length, mouse  $\mu$ 2 (1–141), rat  $\alpha$  (1–621) as a C-terminal GST fusion, and rat  $\beta$ 2 (1–591) fused to an N-terminal 6xHis tag. TEV cleavage sites were introduced between the affinity tags and the protein. The above protein sequences have been compared with that of sooty mangabey (SMM). The following are 100% identical: Rat  $\beta$ 2 (uniprot: P62944) vs SMM  $\beta$ 2 (A0A2K5LRZ0); Rat  $\sigma$ 2 (P62744) vs SMM  $\sigma$ 2 (A0A2K5LIR6); Mouse  $\mu$ 2 (Q3TWW4) and SMM  $\mu$ 2 (A0A2K5NQG4). There are four differences between the Rat  $\alpha$  (Q66HM2) and SMM  $\alpha$  (A0A2K5NR50) core, which are at residues 8, 137, 403 and 557. None of these residues are in the  $\sigma$ 2 or Nef binding interface. GST tagged AP2<sup>hemi</sup> consists of rat  $\alpha$  (1–396) with an N-terminal GST tag and rat  $\sigma$ 2 full-length, the minimal construct binding to HIV-1 NL4–3 Nef (Ren et al., 2014). For all structural and in vitro experiments, the SIVsmm Fwr1 Nef C55A construct bearing the single Cys193 was used, which is referred to as wild-type of SIVsmm Nef. All bacterial expression constructs used in this study are listed in the Key Resources Table.

For MBP pull down or binding assay, SIVsmm Nef wild-type and mutants were subcloned into LIC 2BT vector (Macrolab, UC Berkeley), and were expressed as TEV-cleavable N-terminal 6xHis fusions. DNAs coding for the tetherin tail (2–26) from rhesus macaque or sooty mangabey were codon-optimized using DNAsworks server (Hoover and Lubkowski, 2002) for *E. coli* expression. Rhesus tetherin was first fused to a C-terminal MBP tag and then subcloned into the LIC 2BT vector, which was used to generate proteins for MBP pull down assays. Rhesus tetherin was also subcloned into pGST2, yielding a fusion with an N-terminal GST and a TEV cleavage site for FP assays (Sheffield et al., 1999). For cryo-EM, a PCR fragment encoding sooty mangabey tetherin (4–26)-C2S-10aa linker-SIVsmm Nef (1–251)-C55A was subcloned into pMBP2, and the protein was expressed with an N-terminal TEV cleavable MBP tag and C-terminal uncleavable 6xHis tag.

**Protein expression and purification**—Wild-type and mutant AP2  $^{14}\text{C}$  complexes were expressed in BL21 (DE3) pLysS strain (Promega, Madison, WI) by induction at 23 °C overnight. The cells were lysed by sonication in 50 mM Tris pH 8.0, 300 mM NaCl, 10% glycerol, 3 mM  $\beta$ -mercaptoethanol ( $\beta$ ME), 20 mM imidazole and 2 mM PMSF. The clarified lysate was first purified on a Ni-NTA column (Qiagen, Valencia, CA). The eluate was further purified on glutathione-Sepharose 4B resin (GE healthcare, Piscataway, NJ). After TEV cleavage at 4 °C overnight, the sample was concentrated and then loaded onto a HiLoad 16/60 Superdex 200 column (GE healthcare) in the sample buffer of 20 mM Tris pH 8.0, 150 mM NaCl, 0.1 mM TCEP. The AP2  $^{14}\text{C}$  fractions were passed through 1 ml of glutathione-Sepharose 4B resin to capture the GST tag, concentrated, and flash-frozen in liquid  $\text{N}_2$ .

His-tagged SIVsmm Nef constructs were expressed in BL21 (DE3) star cells (Life technologies, Grand Island, NY), and induced with 0.3 mM IPTG at 25 °C overnight. Purification was carried out using Ni-NTA resin, and samples were eluted with 200 mM imidazole/500 mM NaCl Tris buffer, pH 8. The eluate was subjected to a HiLoad 16/60 Superdex 75 column in high salt buffer of 20 mM Tris pH 8, 500 mM NaCl, 0.1 mM TCEP.

All MBP tagged proteins were expressed in BL21 (DE3) star cells and grown at 30 °C overnight. Cells were induced at 35 °C for 2 hours. The purification of His-tagged tetherin-MBP proteins was carried out by Ni-NTA column, size-exclusion in a HiLoad 16/60 Superdex 200 column, and then a second Ni-NTA column. SMM tetherin-10aa linker-SIVsmm Nef proteins were first purified using a Ni-NTA column, the eluate was diluted 5 times in Q buffer A (30 mM Tris pH 8), and then loaded onto a HiTrap Q HP 5ml column (GE healthcare, Piscataway, NJ). The elution on Q column was performed with a 10 CV linear gradient from 0–1 M NaCl in Q buffer A. The sample fractions were pooled together for TEV cleavage at 4 °C overnight. The TEV cleaved samples was adjusted to final 20 mM imidazole and 500 mM NaCl, and then passed through the second Ni column to remove free MBP tag. The proteins were eluted in 500 mM NaCl/200 mM imidazole buffer and subjected to a 16/60 Superdex 75 column in the same high salt buffer.

GST-tagged tetherin constructs were expressed in BL21 (DE3) star cells, and induced with 0.3mM IPTG at 20 °C overnight. The cleared lysate was purified using glutathione-Sepharose 4B resin. The eluate was concentrated to 1–1.5 ml, and 150  $\mu\text{l}$  of TEV was added to cleave samples at room temperature for 4–5 hours. The cut proteins were then loaded onto a 16/60 Superdex 75 column in the same sample buffer to separate tetherin peptides from MBP and TEV proteins.

**MBP pull down assay**—35  $\mu\text{g}$  of recombinant His-tetherin-MBP proteins were incubated with His- and GST-tagged AP2  $^{14}\text{C}$  (1  $\mu\text{M}$ ) or/and SIVsmm Nef proteins (6  $\mu\text{M}$ ) at 4 °C overnight in 20 mM Tris pH 8, 150 mM NaCl, 0.1 mM TCEP. Then 30  $\mu\text{l}$  Amylose resin (New England Biolabs, Ipswich, MA) was to the mixture and rocked at 4 °C for 2 hours. The beads were washed 4 times, mixed with 50  $\mu\text{l}$  of 2x lithium dodecylsulfate (LDS)/BME buffer and heated at 90°C for 3 min. 19  $\mu\text{l}$  of each sample was subjected to SDS/PAGE gel.

**Tetherin peptide fluorescent labeling**—The wild-type of rh tetherin peptide used in the FP assay consists of residue (2–26): APILYDYRKMPMGDIWKEDGDKRCK. The single cysteine at the C-terminus was used for labeling. The rh tetherin tail differs by only two residues from the SMM tetherin tail, which are both outside the binding region. Alexa Fluor 488 C<sub>5</sub> Maleimide (Thermo Fisher Scientific, Waltham, MA) was dissolved in dimethyl sulfoxide (DMSO). 100 μM of diluted peptide in 1x PBS pH 7.4 was reacted with dye at 1:1.2 molar ratio for 40 min at room temperature. The conjugation reaction was quenched with 100 mM βME at 15 min at room temperature. The samples were then subjected to a HiTrap desalting column in the sample buffer. The Alexa488 labeling efficiency of each peptide was between 96% and 100%.

**Fluorescence polarization binding assay**—Assays were conducted in Greiner 384-well black microplates (784076, Greiner, Monroe, NC). SIVsmm Nef proteins were exchanged from high salt buffer to the sample buffer using a Zeba spin desalting column (7K MWCO, Thermo Fisher Scientific). After desalting, the stock concentration of SIVsmm Nef was adjusted to 80 μM. The Alexa488 labeled tetherin tail peptide was incubated with SIVsmm Nef and AP2 <sup>μ</sup>C in a total volume of 20 μl for 30 min at room temperature. The final concentration of labeled peptide was fixed at 50 nM, while SIVsmm Nef and AP2 <sup>μ</sup>C were kept at a 1:1 molar ratio and titrated from 0.04 to 30 μM in this assay. FP values (mP) were measured using a Synergy H4 microplate reader (excitation at 485 nm and emission at 528 nm, BioTek, Winooski, VT), and plotted as a function of protein concentration using a logarithmic scale (Du, 2015; Moerke, 2009). Measurements were repeated at three times and the data were processed using Origin (OriginLab, Northampton, MA). The binding constant ( $K_d$ ) was fitted using a one-site model.

**SMM tetherin-SIVsmm Nef: AP2 <sup>μ</sup>C cross-linking**—In order to prevent dissociation of the AP-2:Nef complex, intermolecular disulfide cross linking activated by 2,2'-Dipyridyldisulfide (2-PDS) was used to stabilize the SIVsmm Nef-AP-2 interaction. Ser163 in the Nef dileucine loop is within 3 Å of Asn97 in σ2 (PDB: 4NEE) (Ren et al., 2014). The equivalent residue in SIVsmm Nef is Cys193, thus we generated the σ2 N97C/C99S mutation (denoted AP2 <sup>μ</sup>CSS following cross-linking) to induce this intermolecular disulfide bond formation. AP2 <sup>μ</sup>CSS proteins were treated with final 20 mM DTT at 30 °C for 30min, followed by desalting into cross-linking buffer (20 mM Tris pH 8, 150 mM NaCl) using Zeba spin desalting column. SMM tetherin-SIVsmm Nef fusion proteins were also reduced by 20 mM DTT at 30 °C for 30min, followed by desalting into the buffer of 20 mM Tris pH 8, 300 mM NaCl using Zeba spin column. After elution from the desalting column, tetherin-Nef fusion proteins were treated with final 3 mM 2,2'-Dipyridyldisulfide (2-PDS), and incubated at room temperature for 30min (Olsen and Lima, 2013). The activated tetherin-Nef samples were desalted into 20mM Tris PH 8, 150mM NaCl to remove excess 2,2'-Dipyridyldisulfide. Then the activated samples (final 1.5 μM) were immediately mixed with desalted AP2 <sup>μ</sup>CSS (final 1 μM) and incubated at RT for 30min. The cross-linking mixture was further purified over a HiTrap Q HP 1ml column, and then subjected to a Superdex 200 10/300 GL column in cross-linking buffer. The AP2 <sup>μ</sup>CSS:SMM tetherin (4–26)-C2S-10aa-SIVsmm Nef (1–251)-C55A complex eluted as a single homogenous peak in gel filtration, and no additional products were observed on SDS-PAGE.

**Cryo-EM Data Collection**—AP2  $\mu$ CSS:SMM tetherin (4–26)-C2S-10aa-SIVsmm Nef (1–251)-C55A samples for data collection were prepared on 2/1-thick C-flat holey carbon copper 300-mesh grids that were prepared by plasma cleaning for 30 s at 25 mA using a Pelco easiGlow glow discharger (Ted Pella, Inc.). Complex at 0.6 mgmL<sup>-1</sup> was applied in a 4  $\mu$ L drop to one side of the grid, followed by a 30 second wait time, then plunge frozen into liquid ethane using a Vitrobot mark VI. The humidity was controlled at 100%, 22°C and the grids blotted with Whatman #1 paper using a blot force of 6 for 5 s. Two rounds of data collected (dataset 1 and 2) were performed on a Titan Krios (FEI; BACEM UCB) at a nominal magnification of 105,000 and a magnified pixel size of 1.149 Å pix<sup>-1</sup>. The dose rate was 6.08 e<sup>-</sup>/Å<sup>2</sup>/sec at the sample. Data collection was carried out using SerialEM. Dataset 1, consisting of 1647 movies, used stage shift navigation with 3 exposures per hole and focusing for each hole. Dataset 2 consisted of 10,248 micrographs using image shift navigation. 3 shots per hole were collected in a 3×3 grid of holes, focusing once per 9 holes. The defocus range was 1.00 to 2.5  $\mu$ m. Movies were acquired on a K2 direct electron detector (Gatan) in super-resolution counting mode with a dose fractionated frame rate of 250 ms and total collection time of 8250 ms.

**Cryo-EM Data Processing**—Figure S2 shows the cryo-EM data processing workflow. In brief, gain-corrected movies from two data sets (dataset 1 and 2) were motion corrected using the Relion-3 (Zivanov et al., 2018) MotionCor2 (Zheng et al., 2017) wrapper. Corrected micrographs were inspected visually and micrographs with apparent defects, such as ice, debris contamination, or exposures of the carbon support film, were excluded from further processing. The contrast transfer function (CTF) of non-dose weighted micrographs was estimated using Gctf (Zhang, 2016) for dataset 1 and CTFind4 (Rohou and Grigorieff, 2015) for the dataset 2. After an additional visual cleanup, 622,487 and 5,696,434 particles were picked from 1618 and 9333 micrographs using Gautomatch and Relion Laplacian particle picking for datasets 1 and 2, respectively. Particles were extracted from datasets 1 and 2 with a 256 pixel box size from dose-weighted micrographs and subjected to a single round of 2D classification at 4-fold binning in Relion-3.0 (Kimanius et al., 2016; Scheres, 2012) and cryoSPARC v2 (Punjani et al., 2017), respectively. Obvious “Junk” was removed resulting in 4,107,380 refined particles. A 4 class Ab-initio 3D reconstruction was performed in cryoSPARC v2 on dataset 1, resulting in 2 heterogeneous 3D classes (class 1 and 2), where class 1 was the object of refinement, and two “junk” classes. Using 3D class 1 and class 2, multiple rounds of heterogeneous 3D refinement were performed on dataset 1 resulting in a set of 215,685 particles in class 1 which refined to 4.25 Å resolution. These 215,685 particles were then transferred to Relion-3.0. When needed, cryoSPARC v2 database files were converted using UCSF PyEM (<https://github.com/asarnow/pyem>) and in-house written scripts (<https://github.com/simonfromm/miscEM>) into star files for the use as inputs in Relion3.0. A single round of 3D classification was run against two low resolution maps simulated from a refined coordinate model built into the original 4.25 Å structure, one containing Nef and the N-terminus of the  $\beta$ 2 subunit of AP2  $\mu$ CSS (class 1) and one lacking both (class 2). This focused 3D classification was run with a low pass filter of 20 Å,  $\tau = 20$ , and no angular refinement. 90,285 particles were classified to generate the map containing Nef and the N-terminus of the  $\beta$ 2 subunit of AP2  $\mu$ C. After further refinement in cryoSPARC v2, final map contained 84,834 particles and refined to 3.7 Å.

The refined particles of dataset 2 were processed using an iterative 2D classification and heterogeneous refinement workflow similarly to dataset 1 (Fig S2). Eventually, 300,243 particles were subject to a round of focused 3D classification in Relion-3.0 identical to the one performed on dataset 1. The resulting 129,701 particles in class 1 were retained and used for a 3D auto-refine run in Relion-3.0 which served as the basis for per-particle CTF refinement and Bayesian polishing in Relion-3.0. After further refinement of the “shiny” particles in cryoSPARC v2, the remaining 128,842 particles were combined with the 84,834 particles remaining from dataset 1 to give a final dataset of 212,541 particles. Two further rounds of 2D classification and selection yielded 159,406 particles. A final round of homogeneous as well as non-uniform refinement was performed separately in cryoSPARC v2 (Fig S2, S3B). The Non-uniform reconstructions reached a resolution of 3.8 Å and the homogeneous reconstruction reached a resolution of 3.9 Å, both according to the FSC 0.143 cutoff. Both maps showed improved density in the regions of primary interest compared to the prior 3.7 Å map reconstruction. After visual inspection of both reconstructions, the map resulting from non-uniform refinement was chosen for atomic model building and coordinate refinement, and density thereof is shown throughout the manuscript.

**Model Building and Refinement**—Rigid body fitting was performed in UCSF Chimera (Pettersen et al., 2004) using as starting models PDB entries 4NEE and 2XA7, followed by manual adjustment in Coot (Emsley et al., 2010). To help alleviate local differences in map quality, two differently filtered and sharpened maps were used during the model building process. Model building in Coot and real-space refinement in phenix (Afonine et al., 2018) was used to improve the model geometry against both a locally filtered and b-factor sharpened map generated through the cryoSPARC v2 filtering/sharpening routine (applied b-factor:  $-145.0 \text{ \AA}^2$ ) and a map generated from the Relion3.0 PostProcess routine (applied b-factor:  $-77.4 \text{ \AA}^2$ ; low-pass filter: 3.8 Å). Real-space refinement as implemented in phenix with a target resolution of 3.8 Å, secondary structure restraints and a weight of 1 was used iteratively with manual adjustments in Coot to refine the atomic coordinate model. EMRinger scores were calculated (Barad et al., 2015) to identify regions requiring further remodeling in Coot. Where clear residue side-chain density was lacking, side chains were not modeled.

The final model-map cross correlation was 0.75, with a map-versus-model FSC0.5 of 4.5 Å (Fig S3D). Model geometry was validated using MolProbity (Davis et al., 2007). All map and model statistics are detailed in Table S1. A cross-validation test was performed to assess overfitting. In brief, atoms of the final coordinate model were perturbed by an average of 0.5 Å and one round of automated real-space-refinement in phenix against one half map of the gold-standard refinement was performed. The resulting map-vs-model FSC curves of the refined model against the same half map (FSCwork) and the second half map (FSCtest) do not diverge significantly indicating the absence of overfitting (Fig. S3E). Table S1 and Figure S3F summarize the completely assembled AP2  $^{\mu}\text{C}^{\text{SS}}\text{:SMM}$  tetherin-SIVsmm Nef coordinate model, with S3F showing representative density for all AP-2 subunits, SIV smmNef and SMM tetherin.

**HDX-MS**—Uncrosslinked SIVsmm Nef- L1–6His was used in all HDX studies. The construct used for HDX contained a deletion of residues 28–36, which are non-conserved in SIVcpz Nef or HIV-1 NL4–3 Nef, and whose presence reduced the stability of the complex. AP2  $\mu$ C was incubated with SMM tetherin-SIVsmm Nef- L1 or 10aa-SIVsmm Nef- L1 at 4 °C overnight. The mixture was purified using Ni-NTA resin, and loaded on a Superdex 200 10/300 GL column. Fractions were pooled and concentrated to 20  $\mu$ M. Amide HDX-MS was initiated by a 20-fold dilution of 20  $\mu$ M sample stock into a D<sub>2</sub>O buffer containing 20 mM HEPES (pD 7.2), 200 mM NaCl and 0.5 mM TCEP at room temperature. After intervals of 30 s–120 s, exchange was quenched at 0 °C with the addition of ice-cold quench buffer (400 mM KH<sub>2</sub>PO<sub>4</sub>/H<sub>3</sub>PO<sub>4</sub>, pH 2.2). The samples were then injected onto an HPLC (Agilent 1100) with in-line peptic digestion and desalting. Desalted peptides were eluted and directly analyzed by an Orbitrap Discovery mass spectrometer (Thermo Scientific). Peptides were identified with tandem MS/MS experiments and a Proteome Discoverer 2.1 (Thermo Scientific) search. Mass analysis of peptide centroids was performed using HDExaminer (Sierra Analytics, Modesto, CA), followed by manual verification of each peptide. The relative deuterium content of the peptic peptides was determined from the centroid of the molecular ion isotope envelope.

**Proviral constructs**—Overlap-extension PCR was used to replace the NL4–3 *nef* in the IRES-eGFP HIV-1 construct by SIVsmm *nef* genes as described (Schindler et al., 2006). The integrity of all PCR-derived inserts was confirmed by sequencing. The control HIV-1 NL4–3 *env*\* *vpu* IRES-eGFP constructs expressing the NL4–3 and SIVmac239 Nefs or containing a disrupted *nef* gene have been previously described (Wildum et al., 2006). All proviral constructs used in this study are listed in the Key Resources Table.

**Expression vectors**—*Nef* genes were amplified by PCR with flanking primers introducing XbaI and MluI restriction sites for cloning into the bi-cistronic CMV promoter-based pCG IRES eGFP vector as described (Schindler et al., 2006). pCG SMM tetherin and pBJ6 human SERINC5-HA protein expression vectors have been previously described (Kmiec et al., 2018; Munch et al., 2007).

**Western blots**—To examine the expression of SIVsmm Nef proteins, HEK293T cells were transfected in 12-well dishes with 2.5  $\mu$ g DNA of pCG IRES eGFP vectors expressing AU1-tagged Nefs. Two days post-transfection, cells were lysed and proteins separated, blotted and detected as previously described (Kmiec et al., 2018).

**Flow cytometry**—CD4, MHC-I, CD28, CD3, CXCR4 and tetherin surface levels and GFP reporter molecules in PBMCs were measured as described previously (Joas et al., 2018). To analyze cell surface receptor modulation in primary cells, PBMCs were infected with VSV-G-pseudotyped HIV-1 NL4–3 IRES eGFP expressing different *nef* alleles. Three days post infection, cells were stained for CD4 (Life Technologies, MHCD0405), CD3 (BD, 555333), MHC I (Dako, R7000), CD28 (BD, 348047), or CXCR4 (BD, 555976) and analyzed by fluorescence-activated cell sorting (FACS). To calculate the specific effect of Nef on receptor cell surface expression, the mean fluorescence intensities obtained for cells

coexpressing Nef and GFP were normalized to those obtained with the *nef*<sup>\*</sup> construct expressing GFP only (100%).

**Virus stocks**—To generate virus stocks, HEK293T cells were co-transfected with the proviral HIV-1 NL4-3 constructs encoding containing various *nef* alleles and a plasmid (pHIT-G) expressing VSV-G to achieve comparably high infection levels for flow cytometric analysis and replication kinetics. Two days post-transfection, supernatants containing infectious virus were harvested. The amount of HIV-1 capsid protein was quantified by p24 antigen ELISA for normalization of the virus dose.

**Viral infectivity**—Virus infectivity was determined using TZM-bl cells. Briefly, the cells were sown out in 96-well dishes in a volume of 100  $\mu$ l and infected with virus stocks produced by transfected HEK293T cells. Three days post-infection, viral infectivity was detected using the Gal-Screen kit from Applied Biosystems as recommended by the manufacturer.  $\beta$ -galactosidase activity was quantified as relative light units per second using the Orion microplate luminometer.

**SERINC5 antagonism**—To measure Nef-mediated SERINC5 counteraction, HEK293T cells were co-transfected using calcium phosphate with 1.5  $\mu$ g of HIV-1 NL4-3 *env*<sup>\*</sup> *vpu* IRES GFP reporter proviral constructs containing various *nef* alleles, 0.05 $\mu$ g pCAGGS\_NL4-3 FLAG-tag *env* or 0.25 $\mu$ g pHIT VSV-g expression plasmid, and 1.25  $\mu$ g pBJ6-SERINC5-HA expression plasmid or pBJ6-empty vector (12-well format). The HIV-1 NL4-3 *env*<sup>\*</sup> *vpu nef*<sup>-</sup> construct was used as a negative control, whereas HIV-1 NL4-3 *env*<sup>\*</sup> *vpu nef*<sup>-</sup> pseudotyped with VSV-G as well as HIV-1 NL43 *env*<sup>\*</sup> *vpu nef*<sup>+</sup> IRES eGFP and HIV-1 NL43 *env*<sup>\*</sup> *vpu* SIVmac239 *nef* IRES eGFP served as positive controls. Two days post-transfection cell supernatants were harvested and infectious HIV-1 yield was quantified by TZM-bl infection assay. Yields obtained in the presence of pBJ6 SERINC5-HA were normalized to the corresponding pBJ6 empty vector controls (100%) for each virus.

**Tetherin antagonism**—To measure Nef-mediated SMM tetherin counteraction, HEK293T cells were co-transfected using calcium phosphate method with 4  $\mu$ g HIV-1 NL4-3 provirus lacking Vpu expression ( *vpu*), 1  $\mu$ g Nef expression vector or empty vector as well as increasing amounts of SMM tetherin DNA. Two days post-transfection, supernatants and cells were harvested. Infectious HIV-1 yield was quantified by a 96-well TZM-bl infection assay whereas p24 concentration was determined by p24 ELISA quantification of cell free (CF) and cell associated (CA) capsid p24 antigen. Release was calculated as the percentage of CF p24 out of total (CF + CA) produced p24 antigen.

**SIVmac239 Nef analysis**—HEK293T cells were co-transfected with 5  $\mu$ g of SIVmac239 IRES-eGFP proviral constructs encoding wild-type or mutant Nef proteins and 1  $\mu$ g VSV-G expression vector. Two days post-transfection, virus stocks were harvested and concentrated six times using Amicon Ultra-15 centrifugal filter units (100 kDa). Rhesus PBMCs were isolated from rhesus monkey whole blood (provided by Simian lab Europe, Strasbourg) by Ficoll gradient centrifugation and stimulated with IL-2 and PHA for 3 days prior to infection. Three million cells were infected with a total of 300  $\mu$ l virus stock using



spinoculation at 1,200 rpm and 37°C for 2 hours. After spinoculation, 300 µl supernatant were removed before the cells were washed in 3 ml DPBS to remove input virus. Three days post infection, cell surface expression of CD4, CD3, MHC-I and tetherin was determined by flow cytometry. Antibodies used were: CD4 PerCP-Cy5.5-coupled, BD, 552838; CD3 V450-coupled, BD, 560351; MHC-I PE-coupled, BD, 555553; tetherin APC-coupled, Biolegend, 348410 or the respective isotype controls (IgG1κ PerCP-Cy5.5-coupled, BD, 552834; IgG1κ V450-coupled, BD, 560373; IgG1κ PE-coupled, BD, 555749; IgG1κ APC-coupled, Biolegend, 400122).

## QUANTIFICATION AND STATISTICAL ANALYSIS

**Statistical analysis**—For assays performed in Figures 1,3–5, mean measurements were processed using Origin (OriginLab, Northampton, MA). The mean activities in Figure 6 and Figure S6 were compared using Student's t-test. Similar results were obtained with the Mann Whitney U test. The software package StatView version 4.0 (Abacus Concepts, Berkeley, CA) was used for these calculations. All data in these figures are shown as the mean of at least three independent experiments ± SEM. Significance differences are indicated as: \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ . Statistical parameters are specified in the figure legends.

## DATA AND CODE AVAILABILITY

**Image processing and modeling software**—All software and code is available as detailed in the key resources table.

**Cryo-EM map, raw data and model accession numbers**—EM density has been deposited in the EMDB with accession code EMD-20217. Atomic coordinates have been deposited in the PDB with the accession code 6OWT. See also Table S1

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments

We thank D. Toso, S. Fromm, and A. Yokom for cryo-EM support and advice and D. Sauter for comments on the manuscript. Access to the FEI Titan Krios was provided through the BACEM UCB facility. This research was supported by NIH grants R01 AI120691 (X. R.), P50 GM082250 (J. H. H.), F32 GM125209 (C. Z. B.) and an Advanced ERC grant 'Anti-Virome' and DFG-funded SFB 1279 and SPP 1923 (F. K.). Additional support was provided by a generous gift from the Andrew Dougherty Vision Foundation (C.Z.B.)

## References

- Afonine PV, Poon BK, Read RJ, Sobolev OV, Terwilliger TC, Urzhumtsev A, and Adams PD (2018). Real-space refinement in PHENIX for cryo-EM and crystallography. *Acta Crystallogr D Struct Biol* 74, 531–544. [PubMed: 29872004]
- Aiken C, Konner J, Landau NR, Lenburg ME, and Trono D (1994). Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain. *Cell* 76, 853–864. [PubMed: 8124721]

- Barad BA, Echols N, Wang RY, Cheng Y, DiMaio F, Adams PD, and Fraser JS (2015). EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy. *Nat Methods* 12, 943–946. [PubMed: 26280328]
- Bresnahan PA, Yonemoto W, Ferrell S, Williams-Herman D, Geleziunas R, and Greene WC (1998). A dileucine motif in HIV-1 Nef acts as an internalization signal for CD4 downregulation and binds the AP-1 clathrin adaptor. *Curr Biol* 8, 1235–1238. [PubMed: 9811606]
- Canagarajah BJ, Ren X, Bonifacino JS, and Hurley JH (2013). The clathrin adaptor complexes as a paradigm for membrane-associated allostery. *Protein Sci* 22, 517–529. [PubMed: 23424177]
- Chaudhuri R, Lindwasser OW, Smith WJ, Hurley JH, and Bonifacino JS (2007). Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the AP2 clathrin adaptor. *J Virol* 81, 3877–3890. [PubMed: 17267500]
- Collins DR, and Collins KL (2014). HIV-1 accessory proteins adapt cellular adaptors to facilitate immune evasion. *PLoS Pathog* 10, e1003851. [PubMed: 24465204]
- Craig HM, Pandori MW, and Guatelli JC (1998). Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. *Proc Natl Acad Sci U S A* 95, 11229–11234. [PubMed: 9736718]
- Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB 3rd, Snoeyink J, Richardson JS, et al. (2007). MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res* 35, W375–383. [PubMed: 17452350]
- Du Y (2015). Fluorescence polarization assay to quantify protein-protein interactions in an HTS format. *Methods Mol Biol* 1278, 529–544. [PubMed: 25859974]
- DuBridges RB, Tang P, Hsia HC, Leong PM, Miller JH, and Calos MP (1987). Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. *Molecular and cellular biology* 7, 379–387. [PubMed: 3031469]
- Emsley P, Lohkamp B, Scott WG, and Cowtan K (2010). Features and development of Coot. *Acta Crystallogr D Biol Crystallogr* 66, 486–501. [PubMed: 20383002]
- Fouchier RA, Meyer BE, Simon JH, Fischer U, and Malim MH (1997). HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. *EMBO J* 16, 4531–4539. [PubMed: 9303297]
- Heusinger E, Deppe K, Sette P, Krapp C, Kmiec D, Kluge SF, Marx PA, Apetrei C, Kirchhoff F, and Sauter D (2018). Preadaptation of Simian Immunodeficiency Virus SIV<sub>smm</sub> Facilitated Env-Mediated Counteraction of Human Tetherin by Human Immunodeficiency Virus Type 2. *J Virol* 92.
- Hoover DM, and Lubkowski J (2002). DNAWorks: an automated method for designing oligonucleotides for PCR-based gene synthesis. *Nucleic Acids Res* 30, e43. [PubMed: 12000848]
- Jackson LP, Kelly BT, McCoy AJ, Gaffry T, James LC, Collins BM, Honing S, Evans PR, and Owen DJ (2010). A large-scale conformational change couples membrane recruitment to cargo binding in the AP2 clathrin adaptor complex. *Cell* 141, 1220–1229. [PubMed: 20603002]
- Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, and Evans DT (2009). Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. *PLoS Pathog* 5, e1000429. [PubMed: 19436700]
- Jia X, Singh R, Homann S, Yang H, Guatelli J, and Xiong Y (2012). Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef. *Nat Struct Mol Biol* 19, 701–706. [PubMed: 22705789]
- Jia X, Weber E, Tokarev A, Lewinski M, Rizk M, Suarez M, Guatelli J, and Xiong Y (2014). Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1. *Elife* 3, e02362. [PubMed: 24843023]
- Joas S, Parrish EH, Gnanadurai CW, Lump E, Sturzel CM, Parrish NF, Learn GH, Saueremann U, Neumann B, Rensing KM, et al. (2018). Species-specific host factors rather than virus-intrinsic virulence determine primate lentiviral pathogenicity. *Nat Commun* 9, 1371. [PubMed: 29636452]
- Kimanius D, Forsberg BO, Scheres SH, and Lindahl E (2016). Accelerated cryo-EM structure determination with parallelisation using GPUs in RELION-2. *Elife* 5.

- Kluge SF, Mack K, Iyer SS, Pujol FM, Heigele A, Learn GH, Usmani SM, Sauter D, Joas S, Hotter D, et al. (2014). Nef proteins of epidemic HIV-1 group O strains antagonize human tetherin. *Cell Host Microbe* 16, 639–650. [PubMed: 25525794]
- Kmiec D, Akbil B, Ananth S, Hotter D, Sparrer KMJ, Sturzel CM, Trautz B, Ayouba A, Peeters M, Yao Z, et al. (2018). SIVcol Nef counteracts SERINC5 by promoting its proteasomal degradation but does not efficiently enhance HIV-1 replication in human CD4+ T cells and lymphoid tissue. *PLoS Pathog* 14, e1007269. [PubMed: 30125328]
- Kueck T, Foster TL, Weinelt J, Sumner JC, Pickering S, and Neil SJ (2015). Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors. *PLoS Pathog* 11, e1005141. [PubMed: 26317613]
- Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, and Schwartz O (1998). Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. *Immunity* 8, 483–495. [PubMed: 9586638]
- Le Tortorec A, and Neil SJ (2009). Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. *J Virol* 83, 11966–11978. [PubMed: 19740980]
- Leonard JA, Filzen T, Carter CC, Schaefer M, and Collins KL (2011). HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements. *J Virol* 85, 6867–6881. [PubMed: 21543478]
- Mack K, Starz K, Sauter D, Langer S, Bibollet-Ruche F, Learn GH, Sturzel CM, Leoz M, Plantier JC, Geyer M, et al. (2017). Efficient Vpu-Mediated Tetherin Antagonism by an HIV-1 Group O Strain. *J Virol* 91.
- Malim MH, and Bieniasz PD (2012). HIV Restriction Factors and Mechanisms of Evasion. *Cold Spring Harbor perspectives in medicine* 2, a006940. [PubMed: 22553496]
- Manrique S, Sauter D, Horenkamp FA, Lulf S, Yu H, Hotter D, Anand K, Kirchoff F, and Geyer M (2017). Endocytic sorting motif interactions involved in Nef-mediated downmodulation of CD4 and CD3. *Nat Commun* 8, 442. [PubMed: 28874665]
- Moerke NJ (2009). Fluorescence Polarization (FP) Assays for Monitoring Peptide-Protein or Nucleic Acid-Protein Binding. *Curr Protoc Chem Biol* 1, 1–15. [PubMed: 23839960]
- Morris KL, Buffalo CZ, Sturzel CM, Heusinger E, Kirchoff F, Ren X, and Hurley JH (2018). HIV-1 Nefs Are Cargo-Sensitive AP-1 Trimerization Switches in Tetherin Downregulation. *Cell* 174, 659–671 e614. [PubMed: 30053425]
- Munch J, Rajan D, Schindler M, Specht A, Rucker E, Novembre FJ, Nerrienet E, Muller-Trutwin MC, Peeters M, Hahn BH, et al. (2007). Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. *J Virol* 81, 13852–13864. [PubMed: 17928336]
- Neil SJ, Zang T, and Bieniasz PD (2008). Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. *Nature* 451, 425–430. [PubMed: 18200009]
- Olsen SK, and Lima CD (2013). Structure of a ubiquitin E1-E2 complex: insights to E1-E2 thioester transfer. *Mol Cell* 49, 884–896. [PubMed: 23416107]
- Pereira EA, and daSilva LL (2016). HIV-1 Nef: Taking Control of Protein Trafficking. *Traffic* 17, 976–996. [PubMed: 27161574]
- Petterson EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, and Ferrin TE (2004). UCSF Chimera--a visualization system for exploratory research and analysis. *J Comput Chem* 25, 1605–1612. [PubMed: 15264254]
- Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, and Kabat D (1998). Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. *J Virol* 72, 2855–2864. [PubMed: 9525605]
- Punjani A, Rubinstein JL, Fleet DJ, and Brubaker MA (2017). cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. *Nat Methods* 14, 290–296. [PubMed: 28165473]
- Ren X, Farias GG, Canagarajah BJ, Bonifacino JS, and Hurley JH (2013). Structural basis for recruitment and activation of the AP-1 clathrin adaptor complex by Arf1. *Cell* 152, 755–767. [PubMed: 23415225]

- Ren X, Park SY, Bonifacino JS, and Hurley JH (2014). How HIV-1 Nef hijacks the AP-2 clathrin adaptor to downregulate CD4. *Elife* 3, e01754. [PubMed: 24473078]
- Rohou A, and Grigorieff N (2015). CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *J Struct Biol* 192, 216–221. [PubMed: 26278980]
- Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL, McCauley SM, Nowosielska A, Antonarakis SE, Luban J, et al. (2015). HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. *Nature* 526, 212–217. [PubMed: 26416734]
- Sauter D, and Kirchhoff F (2019). Key Viral Adaptations Preceding the AIDS Pandemic. *Cell Host Microbe* 25, 27–38. [PubMed: 30629915]
- Sauter D, Schindler M, Specht A, Landford WN, Munch J, Kim KA, Votteler J, Schubert U, Bibollet-Ruche F, Keele BF, et al. (2009). Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. *Cell Host Microbe* 6, 409–421. [PubMed: 19917496]
- Scheres SH (2012). RELION: implementation of a Bayesian approach to cryo-EM structure determination. *J Struct Biol* 180, 519–530. [PubMed: 23000701]
- Schindler M, Munch J, Kutsch O, Li H, Santiago ML, Bibollet-Ruche F, Muller-Trutwin MC, Novembre FJ, Peeters M, Courgnaud V, et al. (2006). Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. *Cell* 125, 1055–1067. [PubMed: 16777597]
- Schmokel J, Li H, Bailes E, Schindler M, Silvestri G, Hahn BH, Apetrei C, and Kirchhoff F (2009). Conservation of Nef function across highly diverse lineages of SIVsmm. *Retrovirology* 6, 36. [PubMed: 19358735]
- Schmokel J, Sauter D, Schindler M, Leendertz FH, Bailes E, Dazza MC, Saragosti S, Bibollet-Ruche F, Peeters M, Hahn BH, et al. (2011). The presence of a vpu gene and the lack of Nef-mediated downmodulation of T cell receptor-CD3 are not always linked in primate lentiviruses. *J Virol* 85, 742–752. [PubMed: 21068258]
- Schouest B, Weiler AM, Janaka SK, Myers TA, Das A, Wilder SC, Furlott J, Baddoo M, Flemington EK, Rakasz EG, et al. (2018). Maintenance of AP-2-Dependent Functional Activities of Nef Restricts Pathways of Immune Escape from CD8 T Lymphocyte Responses. *J Virol* 92.
- Selleck W, and Tan S (2008). Recombinant protein complex expression in *E. coli*. *Curr Protoc Protein Sci* Chapter 5, Unit 5 21.
- Serra-Moreno R, Zimmermann K, Stern LJ, and Evans DT (2013). Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. *PLoS Pathog* 9, e1003487. [PubMed: 23853598]
- Sheffield P, Garrard S, and Derewenda Z (1999). Overcoming expression and purification problems of RhoGDI using a family of “parallel” expression vectors. *Protein Expr. Purif* 15, 34–39. [PubMed: 10024467]
- Shen QT, Ren X, Zhang R, Lee IH, and Hurley JH (2015). HIV-1 Nef hijacks clathrin coats by stabilizing AP-1:Arf1 polygons. *Science* 350, aac5137. [PubMed: 26494761]
- Traub LM, and Bonifacino JS (2013). Cargo Recognition in Clathrin-Mediated Endocytosis. *Cold Spring Harbor Perspectives in Biology* 5.
- Usami Y, Wu Y, and Gottlinger HG (2015). SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. *Nature* 526, 218–223. [PubMed: 26416733]
- Wildum S, Schindler M, Munch J, and Kirchhoff F (2006). Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. *J Virol* 80, 8047–8059. [PubMed: 16873261]
- Zhang F, Landford WN, Ng M, McNatt MW, Bieniasz PD, and Hatzioannou T (2011). SIV Nef proteins recruit the AP-2 complex to antagonize Tetherin and facilitate virion release. *PLoS Pathog* 7, e1002039. [PubMed: 21625568]
- Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, Johnson MC, Munch J, Kirchhoff F, Bieniasz PD, and Hatzioannou T (2009). Nef proteins from simian immunodeficiency viruses are tetherin antagonists. *Cell Host Microbe* 6, 54–67. [PubMed: 19501037]
- Zhang K (2016). Gctf: Real-time CTF determination and correction. *J Struct Biol* 193, 1–12. [PubMed: 26592709]

Zheng SQ, Palovcak E, Armache JP, Verba KA, Cheng Y, and Agard DA (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat Methods* 14, 331–332. [PubMed: 28250466]

Zivanov J, Nakane T, Forsberg BO, Kimanius D, Hagen WJ, Lindahl E, and Scheres SH (2018). New tools for automated high-resolution cryo-EM structure determination in RELION-3. *Elife* 7.

Author Manuscript


Author Manuscript

Author Manuscript

Author Manuscript


### Highlights

- Cryo-EM structure of AP-2, simian tetherin, and SIVsmm Nef complex at 3.8 Å resolution ·
- Nef refolds the  $\beta$ 2 subunit of AP-2 for binding of the simian tetherin DIWK sequence
- Tetherin binding site is distinct from those of Nef substrates MHC-I, CD3, and CD4
- Tetherin binding site on Nef overlaps with the site for SERINC5 binding



**Figure 1. Reconstitution of the AP2  $\mu^C$ :SMM tetherin-SIVsmm Nef complex.**


(A) Cartoon representation of AP-2 unlocking at the plasma membrane when it interacts with PI(4,5)P<sub>2</sub>. Nef recruits tetherin to the unlocked AP-2 complex where clathrin mediated endocytosis (CME) will result in Nef-induced downregulation of tetherin from the plasma membrane. (B) Simian tetherin tail synergistically binds to AP-2 and SIVsmm Nef. Amylose resin was used to pull down tetherin tail-MBP (rhesus or human), SIVsmm Nef and AP2  $\mu^C$  or the  $\alpha$ - $\sigma$ 2 hemi complex. The pull-down results were visualized by SDS-PAGE and Coomassie staining. (C) Upper panel: Cartoon representation of FP assay. Alexa488 labeled tetherin tail rotates much slower and further causes FP signal increasing while binding to large AP2  $\mu^C$  and SIVsmm Nef. Lower panel: Fluorescence polarization result indicates the cooperative interaction between AP2  $\mu^C$ , rh tetherin and SIVsmm Nef. Fluorescence polarization (in units of mP) is plotted as a function of AP2  $\mu^C$ /SIVsmm Nef concentration ( $\mu$ M) using a logarithmic scale.



**Figure 2. Atomic model of the AP2<sup>μC</sup>:SMM tetherin-SIVsmm Nef complex.**


**(D)** Cryo-EM density map of AP2<sup>μC</sup> bound to SIVsmm Nef and the SMM tetherin cytoplasmic tail **(E)** Ribbon model of AP2<sup>μC</sup> bound to SIVsmm Nef and the SMM tetherin cytoplasmic tail build from the AP2<sup>μC</sup>:SMM tetherin-SIVsmm Nef cryo-EM density map. See also Figure S1–3, Table S1






**Figure 3. Structural model for cooperative binding of SMM tetherin and to SIVsmm Nef to AP2  $\mu^C$ .**

(A) Tetherin  ${}_{14}\text{GDIWK}_{18}$  motif rests in a pocket created by the SIVsmm Nef dileucine loop. The GDIWK motif is further sandwiched by the AP2  $\mu^C$   $\beta 2$  N-terminus and SIVsmm Nef H0 helix. The cryo-EM map density is depicted as a mesh around the SMM tetherin peptide while the Nef and AP-2 are depicted as space filling surface representations. (B) Ribbon representation of the SIVsmm Nef dileucine loop ( ${}_{190}\text{ExxxLV}_{195}$ ) bound to the dileucine binding site of the AP2  $\mu^C$   $\alpha$ - $\sigma 2$ . SMM tetherin peptide is shown to highlight its position relative to the SIVsmm Nef dileucine loop. Fig 3B is rotated  $\sim 90^\circ$  counterclockwise to Fig 3A. (C) Hydrophobic pocket of SIV Nef created by both the SIVsmm Nef dileucine loop and Nef core with the SMM tetherin GDIWK peptide bound and sandwiched by the AP2  $\mu^C$   $\beta 2$  N-terminus and SIVsmm Nef H0 helix. Fig 3C is rotated  $\sim 20^\circ$  clockwise to Fig 3B. Interacting residues are highlighted. (D) Dileucine loop alignment between SIVsmm Nef of the AP2  $\mu^C$ :SMM tetherin: SIVsmm Nef complex and HIV NL4-3 Nef bound to the AP-2  $\alpha$ - $\sigma 2$  hemi complex (PDB: 4NEE). Alignment was performed between AP2  $\mu^C$   $\alpha$ - $\sigma 2$  and AP-2  $\alpha$ - $\sigma 2$  hemi. Fig 3D is rotated  $\sim 90^\circ$  counterclockwise to Fig 3C. Disulfide bond is labeled S-S.




**Figure 4. Structural comparison and analysis of the  $\beta 2$ -adaptin refolding at the SIVsmm Nef interface.**

(A) Alignment of unlocked AP-2  $\beta 2$  from PDB:2XA7 onto the AP2  $\mu C$   $\beta 2$  of the AP2  $\mu C$ :SMM tetherin: SIVsmm Nef structure. (B)  $\beta 2$  mutants in  $\beta$ /Nef interface disrupt cooperative tetherin binding, measured by Fluorescence polarization assay. Figure 4B is rotated  $\sim 45^\circ$  counterclockwise to Fig 4A. (C) Mass spectra of the peptide from  $\beta 2$  (7–18) in AP2  $\mu C$  complex upon SIVsmm Nef (orange) or SMM tetherin-SIVsmm Nef (magenta) binding, compared to unbound state (blue). Gaussian fit on one or two peaks is used to represent the distribution of peak heights of the ion peaks across the m/z values and overlay with mass spectra (straight line). (D) FP assay screens the key residues in tetherin tail. See also Figure S4



**Figure 5. Structural analysis of the SIVsmm Nef tetherin binding pocket.**


(A) Sequence alignment of Nef dileucine loops between SIVsmm Nef and other Nef species. Key residues in SIVsmm Nef for tetherin and AP-2 binding are highlighted. (B) Ribbon representation of SIVsmm Nef mutations investigated with SMM tetherin GDIW motif shown for reference. (C) FP assay indicates that Nef mutations in multi interfaces impair tetherin binding. See also Figure S5



**Figure 6. Residue specificity in tetherin antagonism by SIVsmm Nef.**

(A, B) Cell surface expression of tetherin (A) and infectious virus yield (B) from HEK293T cells following cotransfection with an *env*- and *vpu*-deficient HIV-1 NL4-3 proviral construct encoding the indicated *nef* alleles and eGFP via an IRES and varying amounts of plasmids expressing SMM tetherin. (A) To measure tetherin modulation, cells were stained with an APC-conjugated antibody against tetherin (Biolegend, 348410) or an isotype control (mouse IgG1- $\kappa$ , Biolegend, 400121). Tetherin surface expression was analyzed by flow cytometry and the APC mean fluorescence intensity (MFI) of cells coexpressing Nef and eGFP was normalized to the negative control (*nef*; 100%). Mean of three to six independent experiments  $\pm$  SEM. (B) Infectious virus yield was determined by infection of TZM-bl indicator cells and normalized to that detected in the absence of tetherin (100%). Mean of three to six independent experiments measured in triplicates  $\pm$  SEM. (C) HEK293T cells were co-transfected with *vpu*- and *env*-defective HIV-1 NL4-3 constructs encoding the indicated Nef proteins, a construct expressing the HIV-1 Env glycoprotein, and SERINC5 expression or empty control plasmids. Shown are the mean levels of infectious virus production in the presence of transient SERINC5 expression relative to those obtained in

cells transfected with the control vector (100%). Mean of three to six independent experiments measured in triplicates  $\pm$  SEM. **(D)** To measure receptor modulation, human PBMCs were transduced with VSV-G pseudotyped *env*- and *vpu*-deficient HIV-1 NL4-3 IRES-eGFP constructs containing the indicated *nef* alleles. Cell surface expression of infected (i.e. eGFP positive) cells was normalized to uninfected (i.e. eGFP negative) cells within the same sample before normalization to the negative control (*nef*<sup>-</sup>, 100%). Mean of three independent experiments  $\pm$  SEM. P-values represent differences from the *nef*-defective (grey stars) or wt SIVsmm (black stars) controls. **(E)** Rhesus PBMCs were transduced with VSV-G pseudotyped SIVmac239 IRES-eGFP constructs containing the indicated *nef* alleles. Modulation of CD4, MHC-I, CD3 and tetherin was quantified as described in the legend to figure 6D. Shown are mean values ( $\pm$  SEM) obtained for PBMCs derived from three different rhesus macaques. P-values represent differences from the *nef*-defective (grey stars) or wt SIVsmm (black stars) controls. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ . See also Figure S6



**Figure 7. Comparative structural analysis of Nef-mediated downregulation events.**

(A) A structural model highlighting the two major cargo binding sites targeted by Nef, the dileucine binding site (ExxxLL) and the tyrosine binding site (Yxx $\Phi$ ), and the host factors downregulated by interactions at these sites. (B) A structural model highlighting the Nef mutations that had effects on Nef-dependent downregulation of host tetherin, SERINC5 and immune receptors.

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
APC anti-human CD317 (BST2, Tetherin)	Biolegend	Cat#348410; RRID: AB_2067121
PerCP-Cy <sup>TM</sup> 5.5 Mouse Anti-Human CD4	BD bioscience	Cat#552838; RRID: AB_394488
V450 Mouse Anti-Human CD3	BD bioscience	Cat#560351; RRID: AB_1645168
PE Mouse Anti-Human HLA-ABC	BD bioscience	Cat#555553; RRID: AB_395936
CD4 Monoclonal Antibody (S3.5), APC	Thermo Fisher	Cat#MHCD0405; RRID: AB_1473570
PE Mouse Anti-Human CD3	BD bioscience	Cat#555333; RRID: AB_395740
Monoclonal Mouse Anti-Human HLA-ABC Antigen/RPE	Dako	Cat#R7000; RRID: AB_11192092
PE Mouse Anti-Human CD28	BD bioscience	Cat#348047; RRID: AB_400368
APC Mouse Anti-Human CD184	BD bioscience	Cat#555976; RRID: AB_398616
APC Mouse IgG1, $\kappa$ Isotype Ctrl (FC) Antibody	Biolegend	Cat#400121; RRID: AB_326443
PerCP-Cy <sup>TM</sup> 5.5 Mouse IgG1 $\kappa$ Isotype Control	BD bioscience	Cat#552834; RRID: AB_394484
V450 Mouse IgG1, $\kappa$ Isotype Control	BD bioscience	Cat#560373; RRID: AB_1645606
PE Mouse IgG1, $\kappa$ Isotype Control	BD bioscience	Cat#555749; RRID: AB_396091
Bacterial and Virus Strains		
pCG-SIVsmm FWR1 nef H192D C-AU1 IRES EGFP	This Paper	N/A
pCG-SIVsmm FWR1 nef H196D C-AU1 IRES EGFP	This Paper	N/A
pCG-SIVsmm FWR1 nef H192D/H196D C-AU1 IRES EGFP	This Paper	N/A
pCG-SIVsmm FWR1 nef W203S C-AU1 IRES EGFP	This Paper	N/A
pCG-SIVsmm FWR1 nef H192D/H196D/W203S C-AU1 IRES EGFP	This Paper	N/A
pBR-NL43 vpu env* nef* IRES-eGFP	Wildum et al. 2006	N/A
pBR-NL43 vpu env* IRES-eGFP	Wildum et al. 2006	N/A
pBR-NL43 vpu env* IRES-eGFP_SIVsmmFwr1 nef	Wildum et al. 2006	N/A
pBR-NL43 vpu env* IRES-eGFP_SIVsmmFwr1 nef H192D	This Paper	N/A
pBR-NL43 vpu env* IRES-eGFP_SIVsmmFwr1 nef H196D	This Paper	N/A
pBR-NL43 vpu env* IRES-eGFP_SIVsmmFwr1 nef H192D/H196D	This Paper	N/A
pBR-NL43 vpu env* IRES-eGFP_SIVsmmFwr1 nef W203S	This Paper	N/A
pBR-NL43 vpu env* IRES-eGFP_SIVsmmFwr1 nef H192D/H196D/W203S	This Paper	N/A
pBR-NL43 vpu env* IRES-eGFP SIVmac239 nef	Wildum et al. 2006	N/A
pBR-SIVmac239 IRES-eGFP	Schindler et al. 2006	N/A
pBR-SIVmac239 nef* IRES-eGFP	Schindler et al. 2006	N/A
pBR-SIVmac239_IRES-eGFP nef H192D	This Paper	N/A
pBR-SIVmac239_IRES-eGFP nef H196D	This Paper	N/A
pBR-SIVmac239_IRES-eGFP nef H192D/H196D	This Paper	N/A
pBR-SIVmac239_IRES-eGFP nef W203S	This Paper	N/A
pBR-SIVmac239_IRES-eGFP nef H192D/H196D/W203S	This Paper	N/A

REAGENT or RESOURCE	SOURCE	IDENTIFIER
pHIT-G-VSV-G	Fouchier et al. 1997	N/A
pBJ6 (empty)	Rosa et al. 2015	N/A
pBJ6 SERINC5-HA	Rosa et al. 2015	N/A
pCAGGS_HIV-1 M NL4-3 Env (137 FLAG-tag)	Braun et al. 2019	N/A
pCG-HIV-1 NL4-3 nef 3* IRES-DsRed	Mack et al. 2017	N/A
pCG-rhesus G tetherin DsRed	Mack et al. 2017	N/A
pCG-SIVsmm1 tetherin Fit2	This Paper	N/A
Chemicals, Peptides, and Recombinant Proteins		
2,2'-Dipyridyldisulfide (2-PDS)	Alfa Aesar	A11118, CAS: 2127-03-9
AP-2 $\beta$ 2 1-591 rat	This Paper	P62944
AP-2 $\sigma$ 2 Rat	This Paper	P62744
AP-2 $\mu$ 2 1-141 mouse	This Paper	Q3TWV4
AP-2 $\alpha$ 1-621 rat	This Paper	Q66HM2
AP-2 $\alpha$ 1-396 rat	This Paper	Q66HM2
sooty mangabey tetherin 4-26 C2S SIVsmm Nef 1-251 C55A chimera	This Paper	C3VHQ4/DQ092758
Nef C55A SIVsmm	This Paper	DQ092758
tetherin 2-26 rhesus macaque	This Paper	G0WVJ8
Deposited Data		
AP2 $\mu$ C:SMM tetherin-SIVsmm Nef EM map	This Paper	EMD-20217
AP2 $\mu$ C:SMM tetherin-SIVsmm Nef EM PDB	This Paper	6OWT
Experimental Models: Cell Lines		
Human: HEK293T cells	ATCC	Cat# CRL-3216; RRID: CVCL_0063
Human: TZM-bl cells	NIH	Cat# 8129; RRID: CVCL_B478
Oligonucleotides		
Primers used to generate pCG IRES eGFP expression plasmids and HIV-1 IRES eGFP proviral constructs harboring SIVsmmFwr1 nef	See table S2 of this paper	N/A
Primers used to generate SIVmac239 IRES eGFP proviral constructs harboring mutations in nef	See table S3 of this paper	N/A
Recombinant DNA		
Rat AP-2S1/Mm AP2M1/Rat AP2A1-TEVsite-GST/His-TEVsite-Rat AP2B1 in pST39 vector	This Paper	AP2 $\mu$ C
AP2S1: N97C/C99S in AP2 $\mu$ C in pST39 vector	This Paper	AP2 $\mu$ C <sub>ss</sub>
AP2S1: N97C/C99S in AP2 $\mu$ C in pST39 vector	This Paper	AP2 $\mu$ C- $\beta$ D3A/S5A
AP2B1: K5D/K6E/F7D/pST39 in pST39 vector	This Paper	AP2 $\mu$ C- $\beta$ K5D/K6E/F7D
AP2B1: T8A/T9A in pST39 vector	This Paper	AP2 $\mu$ C- $\beta$ T8A/T9A
AP2B1: K11D/K12D in pST39 vector	This Paper	AP2 $\mu$ C- $\beta$ K11D/K12D
AP2B1: I15D/F16D in pST39 construct	This Paper	AP2 $\mu$ C- $\beta$ I15D/F16D
AP2B1: residue (1-13) truncation in pST39 construct	This Paper	AP2 $\mu$ C- $\beta$ (1-13)
AP2B1: residue (1-23) truncation in pST39 construct	This Paper	AP2 $\mu$ C- $\beta$ (1-23)
Rat AP2S1 (1-143)/GST-TEVsite-Rat AP2A1 (1-396) in pST39 construct	This Paper	GST- $\alpha$ - $\sigma$ 2 hemi



REAGENT or RESOURCE	SOURCE	IDENTIFIER
Rh Tetherin (2–26)-MBP in LIC 2BT vector	This Paper	His-rh Tetherin-MBP
Rh Tetherin (2–26) wild type in pGST2 vector (BamHI/XhoI)	This Paper	GST-rh Tetherin-WT
Rh Tetherin: Y6A/Y8A in pGST2 vector	This Paper	GST-rh Tetherin-Y6A/Y8A
Rh Tetherin: D15R/pGST2 in pGST2 vector	This Paper	GST-rh Tetherin-D15R
Rh Tetherin: I16E in pGST2 vector	This Paper	GST-rh Tetherin-I16E
Rh Tetherin: W17D in pGST2 vector	This Paper	GST-rh Tetherin-W17D
Rh Tetherin: K18D in pGST2 vector	This Paper	GST-rh Tetherin-K18D
Rh Tetherin: E19A in pGST2 vector	This Paper	GST-rh Tetherin-E19A
SIVsmm Nef-C55A in LIC 2BT vector	This Paper	His-SIVsmm Nef-WT
SIVsmm Nef: Y133D in LIC 2BT vector	This Paper	SIVsmm Nef-Y133D
SIVsmm Nef: V180D/S183Y in LIC 2BT vector	This Paper	SIVsmm Nef-V180D/S183Y
SIVsmm Nef: E185A/A186H in LIC 2BT vector	This Paper	SIVsmm Nef-E185A/A186H
SIVsmm Nef: Q187A/E188S in LIC 2BT vector	This Paper	SIVsmm Nef-Q187A/E188S
SIVsmm Nef: D189K in LIC 2BT vector	This Paper	SIVsmm Nef-D189K
SIVsmm Nef: E190K in LIC 2BT vector	This Paper	SIVsmm Nef-E190K
SIVsmm Nef: H192D in LIC 2BT vector	This Paper	SIVsmm Nef-H192D
SIVsmm Nef: L194A/V195A in LIC 2BT vector	This Paper	SIVsmm Nef-L194A/V195A
SIVsmm Nef: H196D in LIC 2BT vector	This Paper	SIVsmm Nef-H196D
SIVsmm Nef: Q199A in LIC 2BT vector	This Paper	SIVsmm Nef-Q199A
SIVsmm Nef: W203S in LIC 2BT vector	This Paper	SIVsmm Nef-W203S
SIVsmm Nef: D204S/P206A in LIC 2BT vector	This Paper	SIVsmm Nef-D204S/P206A
Smm tetherin (4–26)-C9S/C25S-10aa linker (GSDEASEGSG)-SIVsmm Nef (1–251)-C55A-6xHis in pMBP2 vector (BamHI/XhoI)	This Paper	smm tetherin-SIVsmm Nef-6His
smm tetherin-C2S-10aa linker-SIVsmm Nef-C55A- (28–36)-6xHis in pMBP2 vector (BamHI/XhoI)	This Paper	smm tetherin-SIVsmm Nef- L1
10aa linker (GSDEASEGSG)-SIVsmm Nef (1–251)-C55A- (28–36)-6xHis in pMBP2 vector (BamHI/XhoI)	This Paper	10link-SIVsmm Nef- L1
Software and Algorithms		
MotionCor2–1.0.0	Zheng et al., 2017	<a href="http://msg.ucsf.edu/em/software/motioncor2.html">http://msg.ucsf.edu/em/software/motioncor2.html</a>
Gct-v1.06	Zhang, 2016	<a href="https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/">https://www.mrc-lmb.cam.ac.uk/kzhang/Gctf/</a>
CTFIND4.1.12	Rhou and Grigorieff, 2015	<a href="http://grigoriefflab.janelia.org/ctffind4">http://grigoriefflab.janelia.org/ctffind4</a>
Relion-3.06	Zivanov et al., 2018	<a href="https://github.com/3dem/relion">https://github.com/3dem/relion</a>
cryoSPARC v2.8.0	Punjani et al., 2017	<a href="https://cryosparc.com">https://cryosparc.com</a>
UCSF Chimera1.13.1	Pettersen et al., 2004	<a href="https://www.cgl.ucsf.edu/chimera/download.html">https://www.cgl.ucsf.edu/chimera/download.html</a>
PyEM	Daniel Asarnow, UCSF; Github	<a href="https://github.com/asarnow/pyem">https://github.com/asarnow/pyem</a>
PyEM support scripts	This Paper	<a href="https://github.com/simonfromm/miscEM">https://github.com/simonfromm/miscEM</a>
Coot 0.9	Emsley et al., 2010	<a href="https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/cool/">https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/cool/</a>

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Phenix 1.12	Adams et al., 2010	<a href="https://www.phenix-online.org/download/">https://www.phenix-online.org/download/</a>
emRinger	Barad et al., 2015	<a href="https://github.com/fraser-lab/EMRinger">https://github.com/fraser-lab/EMRinger</a>
MolProbity	Davis et al., 2007	Phenix package
HDExaminer	Sierra Analytics, Modesto, CA	<a href="http://massspec.com">http://massspec.com</a>
Proteome Discoverer 2.1	Thermo Scientific, Waltham, MA	<a href="http://www.thermofisher.com/">http://www.thermofisher.com/</a>
StatView version 4.0	Abacus Concepts, Berkeley, CA	<a href="http://www.macintoshrepository.org/10824-statview-4-0">http://www.macintoshrepository.org/10824-statview-4-0</a>
Origin	OriginLab, Northampton, MA	<a href="http://www.originlab.com">http://www.originlab.com</a>

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript